Journal of Materials Science and Nanomaterials
Open Access

Nanomedicine; Drug delivery systems; Therapeutic applications; Nanoparticles; Targeted therapy; Biomedical engineering

Introduction

Nanomedicine, an innovative frontier in healthcare, employs nanotechnology—the manipulation and application of materials at the nanoscale—to revolutionize medical diagnostics, treatment, and prevention strategies. Over the past few decades, the field has garnered significant attention for its ability to enhance the precision and efficacy of drug delivery systems. The nanoscale properties of these materials, typically ranging from 1 to 100 nanometers, afford unique physicochemical characteristics such as high surface area-to-volume ratios, tunable surface properties, and the ability to encapsulate diverse therapeutic agents. These features make nanomedicine particularly effective in addressing challenges posed by traditional therapeutic approaches [1]. Conventional drug delivery systems often struggle with issues such as limited solubility, rapid degradation of active pharmaceutical ingredients (APIs), and nonspecific biodistribution, which can lead to suboptimal therapeutic outcomes and systemic toxicity. Nanoparticle-based delivery platforms have emerged as a promising solution, offering controlled release mechanisms, targeted delivery to specific tissues or cells, and improved bioavailability. Liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles represent some of the most widely researched nanocarriers, each offering unique advantages tailored to specific medical applications [2]. Cancer therapy exemplifies the transformative potential of nanomedicine. Nanoparticles can be engineered to accumulate selectively within tumor tissues via the enhanced permeability and retention (EPR) effect. Furthermore, functionalization with ligands enables active targeting of cancer cells, minimizing off-target effects and enhancing therapeutic efficacy. Beyond oncology, nanomedicine holds promise in combating infectious diseases, neurodegenerative disorders, and chronic illnesses such as diabetes. For instance, nanocarriers have enabled the development of long-acting antiretroviral therapies, overcoming adherence challenges in HIV treatment [3]. Despite its significant potential, the clinical translation of nanomedicine faces several barriers. Issues such as the complexity of nanoparticle synthesis, potential immunogenicity, and long-term biocompatibility must be addressed to facilitate widespread adoption. Regulatory frameworks also need to evolve to accommodate the unique characteristics of nanoscale interventions [4]. This paper aims to provide a comprehensive overview of recent advancements in nanomedicine, with a particular focus on drug delivery systems and their therapeutic applications. We will also discuss the current challenges and potential strategies to overcome them, paving the way for the next generation of nanomedical innovations [5].

Results

The integration of nanotechnology into drug delivery systems has yielded remarkable advancements in therapeutic efficacy and patient outcomes. Among the various nanocarriers, liposomes have emerged as a gold standard for drug delivery due to their biocompatibility, low toxicity, and ability to encapsulate both hydrophilic and hydrophobic drugs. Liposomal formulations of chemotherapeutics such as doxorubicin and paclitaxel have demonstrated improved pharmacokinetics and reduced systemic toxicity, revolutionizing cancer treatment protocols. Polymeric nanoparticles have also garnered attention for their versatility and biodegradability. These carriers enable controlled drug release, ensuring sustained therapeutic levels over extended periods. For example, poly(lactic-co-glycolic acid) (PLGA) nanoparticles have been widely employed for the delivery of anticancer drugs, peptides, and vaccines. Dendrimers, with their highly branched and tunable architecture, offer precise drug-loading capacities and functionalization options, making them ideal for targeted delivery. Metallic nanoparticles, such as gold and silver nanoparticles, have found applications in both therapy and diagnostics. Gold nanoparticles, in particular, have been explored for photothermal therapy, leveraging their ability to convert light into heat to ablate tumor tissues. Additionally, they serve as imaging agents, enhancing diagnostic accuracy in oncology. Clinical trials have demonstrated the efficacy of nanomedicine in diverse therapeutic areas. For instance, lipid nanoparticle-based delivery systems played a pivotal role in the rapid development of COVID-19 mRNA vaccines, showcasing the scalability and potential of nanotechnology in addressing global health crises. Moreover, nanocarrier-based formulations have improved treatment adherence in chronic conditions by enabling once-weekly or monthly dosing regimens. However, the transition from bench to bedside is not without challenges. The scalability of nanoparticle production, coupled with stringent regulatory requirements, often delays clinical translation. Addressing these barriers will be critical to realizing the full potential of nanomedicine.

Discussion

The advancements in nanomedicine have significantly transformed drug delivery systems and therapeutic applications, offering unparalleled precision and efficacy. Nanoparticles’ ability to deliver drugs in a controlled and targeted manner has mitigated several limitations of conventional therapies, particularly in oncology and chronic disease management. However, the field must address critical challenges to ensure its long-term success and sustainability [6]. One significant hurdle lies in the scalability of nanoparticle synthesis. Laboratory-scale production techniques often face difficulties when adapted for large-scale manufacturing, leading to variations in particle size, surface properties, and batch-to-batch consistency. These inconsistencies can impact the efficacy and safety of the final product, posing challenges for regulatory approval. Developing robust and reproducible manufacturing techniques is therefore essential. Another concern is the potential immunogenicity and toxicity of nanocarriers. While many nanoparticles are designed to be biocompatible, their interaction with biological systems can elicit unintended immune responses. Long-term studies are necessary to understand the chronic effects of nanoparticle exposure, particularly in therapies requiring repeated dosing [7]. Regulatory frameworks for nanomedicine also require significant updates to accommodate the unique characteristics of nanoscale interventions. Current guidelines often struggle to address the complexities of nanoparticle characterization, biodistribution, and clearance. Collaborative efforts between researchers, industry stakeholders, and regulatory bodies are needed to develop comprehensive evaluation protocols that ensure both safety and efficacy. Despite these challenges, the future of nanomedicine remains promising. Emerging trends such as artificial intelligence-driven nanoparticle design and the integration of nanotechnology with gene editing tools like CRISPR hold immense potential. These innovations could pave the way for personalized nanomedicine, enabling treatments tailored to individual patient profiles [8].

Conclusion

Nanomedicine represents a paradigm shift in drug delivery systems and therapeutic applications, addressing longstanding challenges in traditional medicine. By leveraging the unique properties of nanoparticles, it has improved drug targeting, reduced systemic toxicity, and enhanced therapeutic outcomes. Breakthroughs in liposomal formulations, polymeric nanoparticles, and metallic nanocarriers underscore the transformative potential of this field, as evidenced by successes in cancer therapy and the development of mRNA vaccines. However, realizing the full potential of nanomedicine requires overcoming significant obstacles, including manufacturing scalability, regulatory complexities, and long-term safety concerns. Continued investment in research and development, coupled with interdisciplinary collaboration, will be essential to address these challenges. Looking ahead, the integration of nanotechnology with emerging fields such as artificial intelligence and precision medicine promises to redefine healthcare delivery. By addressing current limitations and fostering innovation, nanomedicine is poised to unlock new frontiers in personalized and effective treatments, ultimately improving patient care and global health outcomes.

1. Schubert U (2015) Chemistry and fundamentals of the sol-gel process. In the sol-gel handbook 3: 3-27.

Google Scholar, Crossref

2. Ertan A, Kodumuri P, Talu O, Tewari SN (2009) Effect of synthesis time and treatment on porosity of mesoporous silica materials. Adsorption 15: 81-86.

Google Scholar, Crossref

3. Oliveira DM, Andrada AS (2019) Synthesis of ordered mesoporous silica MCM-41 with controlled morphology for potential application in controlled drug delivery system. Ceramica 65: 170-179.

Google Scholar, Crossref

4. Glazneva TS, Rebrov EV, Schouten JC, Paukshtis EA, Ismagilov ZR, et al. (2007) Synthesis and characterization of mesoporous silica thin films as catalyst support on titanium substrate. Thin solid films 515: 6391-6394.

Google Scholar, Crossref

5. Meysam K, Norhayati A (2013) Characterization and modification of mesoporous silica nanoparticles prepared by sol-gel. Journal of Nanomaterials.

Google Scholar, Crossref

6. Lee U, Kim MH, Kwon YU (2006) Kwon Mesoporous thin films with accessible pores from the surface. Bull Korean Chem Soc 27: 808-816.

Google Scholar, Crossref

7. Grosso D, Cagnol F, Soler AA, Crepaidi EL, Amenitsh A, et al. (2004) Fundamentals of mesostructuring through evaporation-induced self-assembly. Adv Func mater 4: 309-322.

Google Scholar, Crossref

8. Jalil MN (2011) The preparation and characterization of mesoporous films for electrochemical applications. PhD Thesis University of Manchester.

Google Scholar